questions for martis, page-20

Your paper thin analysis would carry more gravitas if you knew how to spell "lose"

A blog article full of pithy out of context statements distracts from the matter in hand. Anteo is not the 'next' anything - it's the first nanotech glue for the bio industry.

In fairness I agree that a large buy at these levels would take some cajones and perhaps there is better risk reward elsewhere.

I suggest you talk to management about the status of current projects if you think the current valuation is just 'speculative froth' also your valuation metrics are completely laughable and indicate a poor grasp of ADO's cost of business and future growth - you can't complain its a speccy then try and value it like a mature blue chip.